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Poagulopathy After Successful
ardiopulmonary Resuscitation Following Cardiac Arrest
mplication of the Protein C Anticoagulant Pathway
hristophe Adrie, MD,* Mehran Monchi, MD,† Ivan Laurent, MD,† Suzan Um, BS,‡
. Betty Yan, PHD,‡ Marie Thuong, MD,* Alain Cariou, MD,§ Julien Charpentier, MD,§
ean François Dhainaut, MD§
aint Denis, Massy, and Paris, France; and Indianapolis, Indiana
OBJECTIVES We investigated coagulation abnormalities in out-of-hospital cardiac arrest (OHCA) pa-
tients, with special attention to the protein C anticoagulant pathway.
BACKGROUND Successfully resuscitated cardiac arrest is followed by a systemic inflammatory response and by
activation of coagulation, both of which may contribute to organ failure and neurological
dysfunction.
METHODS Coagulation parameters were measured in all patients admitted after successfully resuscitated
OHCA.
RESULTS At admission, 67 patients had a systemic inflammatory response with increased interleukin-6
and coagulation activity (thrombin-antithrombin complex), reduced anticoagulation (anti-
thrombin, protein C, and protein S), activated fibrinolysis (plasmin-antiplasmin complex),
and, in some cases, inhibited fibrinolysis (increased plasminogen activator inhibitor-1 with a
peak on day 1). These abnormalities were more severe in patients who died within two days
(50 of 67, 75%) and were most severe in patients dying from early refractory shock. Protein
C and S levels were low compared to healthy volunteers and discriminated OHCA survivors
from nonsurvivors. Furthermore, a subgroup of patients had a transient increase in
plasma-activated protein C at admission followed by undetectable levels. This, along with an
increase in soluble thrombomodulin over time, suggests secondary endothelial injury and
dysfunction of the protein C anticoagulant pathway similar to that observed in severe sepsis.
CONCLUSIONS Major coagulation abnormalities were found after successful resuscitation of cardiac arrest.
These abnormalities are consistent with secondary down-regulation of the thrombomodulin-
endothelial protein C receptor pathway. (J Am Coll Cardiol 2005;46:21–8) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.03.046American College of Cardiology Foundation
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sudden death from coronary heart disease before reaching
he hospital occurs in about 225,000 people annually in the
.S. The overall survival rate is low, ranging from 4% to
3% depending on the efficacy of the chain of survival (1,2).
n successfully resuscitated patients admitted to the inten-
ive care unit (ICU), the prognosis remains poor, and
ife-threatening disturbances known as “post-resuscitation
isease” may lead to multiple organ dysfunction and jeop-
rdize neurological recovery (3). Shock often develops
everal hours after hospital admission. It is characterized by
ow cardiac output and is usually reversible within 24 h,
uggesting post-resuscitation myocardial dysfunction asso-
iated with peripheral vasodilation (4). Early death by
ultiple organ failure is associated with low cardiac output
asting longer than 24 h; however, the hemodynamic status
oes not predict the neurological outcome (4). Reperfusion
ailure, ischemia-reperfusion injury, and cerebral injury may
From the *Intensive Care Unit, Delafontaine Hospital, Saint Denis, France;
Intensive Care Unit, Jacques Cartier Hospital, Massy, France; ‡Lilly Research
aboratories, Eli Lilly Company, Indianapolis, Indiana; and §Medical Intensive Care
edicine, Cochin Hospital, University of Paris V, Paris, France. Suzan Um and Dr.
an are employees of Eli Lilly and Company, and Dr. Dhainaut has served as a
onsultant for Eli Lilly and Company. However, this study was a research collabo-
ation effort and was not funded by Lilly.p
Manuscript received October 9, 2004; revised manuscript received February 24,
005, accepted March 15, 2005.e responsible for an overwhelming systemic inflammatory
esponse associated with elevated plasma cytokines, pres-
nce of circulating endotoxin, leukocyte dysregulation, and
drenal dysfunction, a picture similar to that observed in
evere sepsis (5,6). Moreover, a similar systemic inflamma-
ory response has been described in severe cardiogenic shock
ith multiple organ failure (7) or a need for mechanical
irculatory support (8).
Cardiopulmonary resuscitation (CPR) and a return to
pontaneous circulation are associated with marked activa-
ion of blood coagulation, without adequate concomitant
ctivation of endogenous fibrinolysis (9,10). This suggests
hat intravascular fibrin formation and microvascular
hrombosis after cardiac arrest may contribute to organ
ysfunction, including neurological impairment. Consistent
ith this hypothesis, thrombolytic therapy after CPR im-
roved survival in experimental models of induced cardiac
rrest (11,12) and allowed the return of spontaneous circu-
ation after failed initial CPR (13).
Inflammatory and procoagulant host responses are closely
inked not only to infection, but to all inflammatory pro-
esses (14). Inflammatory cytokines activate coagulation and
nhibit fibrinolysis, whereas the procoagulant thrombin
timulates multiple inflammatory pathways (14). Activated
rotein C is an endogenous protein that enhances fibrino-
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Protein C Pathway Alteration After Cardiac Arrest July 5, 2005:21–8ysis, limits thrombin generation, and modulates inflamma-
ion. It is converted from its inactive precursor, protein C,
y thrombin coupled to thrombomodulin. On the other
and, thrombin can have multiple proinflammatory prop-
rties; it activates endothelial cells to express P-selectin,
romotes neutrophil and monocyte adhesion, induces en-
othelial platelet-activating factor formation, and acts as a
hemoattractant for polymorphonuclear neutrophils (15).
dministration of activated protein C significantly reduces
ortality in patients with severe sepsis, a disease of systemic
nflammatory activation (16).
In this study, we investigated the inflammation and
oagulation responses in patients who were successfully
esuscitated after an out-of-hospital cardiac arrest (OHCA).
e directed special attention to the protein C pathway.
ETHODS
atients after OHCA, patients with severe sepsis, and
ealthy volunteers. This study was performed according to
he ethical rules of our institutions (Cochin Hospital, Paris,
rance, and Delafontaine Hospital, Saint Denis, France),
nd informed consent was obtained from the next-of-kin of
ll patients. Cardiac arrest was defined as absence of
pontaneous respiration, palpable heartbeat, and responsive-
ess to stimuli. Consecutive patients older than 16 years of
ge who were successfully resuscitated after OHCA were
rospectively included in the study. Successful resuscitation
as defined as recovery of blood pressure and pulse for more
han 1 h, with or without a continuous catecholamine
nfusion. Both the Simplified Acute Physiology score
SAPS II) (17) and the Logistic Organ Dysfunction (LOD)
core (18) were calculated. We recorded oral anticoagulants
nd/or antiplatelet agents given before or after admission, as
ell as prophylactic heparin therapy. Outcomes identified
hree groups of patients: survivors, all of whom were
onscious; patients who died within four days from early
efractory shock with multiple organ failure; and patients
ho died later from neurological dysfunction with or
ithout a need for initial inotropic support (4–6). Patients
ere excluded from the study if they received thrombolytic
herapy or therapeutic heparin. We also excluded patients
Abbreviations and Acronyms
AT  antithrombin
CPR  cardiopulmonary resuscitation
ICU  intensive care unit
IL  interleukin
LOD  Logistic Organ Dysfunction score
OHCA  out-of-hospital cardiac arrest
PAI  plasminogen activator inhibitor
PAP  plasmin-antiplasmin complex
SAPS II  Simplified Acute Physiology score
sTM  soluble thrombomodulin
TAT  thrombin-antithrombin complexith end-stage liver disease identified on the basis of clinical nvidence or medical history. To check the validity of our
iomarker assay methods, we studied two control groups,
ne composed of patients with severe sepsis meeting Amer-
can College of Chest Physicians/Society of Critical Care
edicine consensus criteria (19) and studied within two
ays of ICU admission, and the other composed of healthy
olunteers.
lood samples. Citrated blood samples (4 ml) were col-
ected and immediately centrifuged at 1,500 g for 10 min.
he plasma was stored at 80°C until analysis. Blood
ollection was performed at ICU admission (day 0) and
aily for the next 7 days (days 1 to 7). In a subset of 16
atients, additional blood samples were collected on days 0,
, and 2 for measuring plasma endogenous activated protein
. Blood samples were drawn into citrated tubes containing
he reversible serine protease inhibitor benzamidine, which
locks the irreversible inhibition of activated protein C by
ndogenous plasma protease inhibitors (20).
ssays. The following assays were performed using an
TA Compact coagulation analyzer (Diagnostica Stago,
snières, France) with Diagnostica Stago test kits. Acti-
ated partial thromboplastin time (STA-PTT A), pro-
hrombin time (STA-Neoplastine Cl plus), protein C (Sta-
lot Protein C), and free protein S (Staclot Protein S) were
easured using coagulation-based activity assays. D-dimer
evels were measured immunoturbidimetrically with the
TA Liatest D-DI latex immunoassay. Antithrombin (AT)
Stachrom ATIII) and plasminogen activator inhibitor
PAI)-1 (Stachrom PAI) levels were quantitated using
hromogenic activity assays. Soluble thrombomodulin
sTM) (Asserachrom Thrombomodulin, Diagnostica
tago), thrombin-antithrombin complex (TAT) (Enzyg-
ost TAT micro, Dade Behring, Marburg, Germany),
lasmin-antiplasmin complex (PAP) (PAP micro ELISA,
RG International Inc., Mountainside, New Jersey), and
nterleukin (IL)-6 (Quantikine Human IL-6 kit, R & D
ystems, Minneapolis, Minnesota) antigen levels were mea-
ured by enzyme immunoassays. Plasma-activated protein C
evels were measured using immunocapture-amidolytic as-
ays, as previously described by Gruber and Griffin (20).
ormal ranges and abbreviations for each of the biomarkers
re reported in the Appendix.
tatistical analysis. Continuous data were expressed as
edians and interquartile ranges. Undetectable levels (levels
elow the detection threshold) were assigned the value 0.
ecause of the high mortality rate within the first few days
n the ICU, the statistical analysis of circulating markers was
onfined to the first two days. Differences between groups
ere evaluated using Mann-Whitney U tests or chi-square
ests. Relationships between two continuous variables were
nalyzed using Spearman’s rank correlation tests. Repeated
easures analysis of variance was used to compare the
ime-course of coagulation markers between survivors and
onsurvivors. For this analysis, levels of coagulation param-
ters were normalized by natural log transformation. After
atural log transformation, the Shapiro-Wilk W test was
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July 5, 2005:21–8 Protein C Pathway Alteration After Cardiac Arrestsed to test for normality, with p values 0.10 indicating a
ormal distribution. For nonsurvivors, missing values after
eath were replaced by the last available value. A p value
0.05 was considered statistically significant. Statistical
ests were run using Stata 7.0 software (Stata Corp., College
tation, Texas).
ESULTS
atient characteristics. We included 67 patients (49 men,
3%) admitted after successful resuscitation of cardiac ar-
est, either to the Delafontaine Hospital ICU (n 35) or to
he Cochin Hospital ICU (n  32). Among them, 43 were
ncluded in a previous study from February 1999 to April
000 (5); the 24 additional patients were included from
ecember 2001 to July 2002. Median SAPS II score was 66
56 to 79), median LOD score was 9 (7 to 12), and median
lasgow Coma Scale score was 3 (3 of 3) at admission
Table 1). Cardiac ischemia was the leading cause of cardiac
rrest (n  39, 58%). All patients received endotracheal
echanical ventilation. Median time from cardiac arrest to
able 1. Baseline Characteristics of Patients Admitted to the ICU
Parameters
All Patients
(n  67)
ge (yrs) 57 (49–69)
APS II score 66 (56–79)
OD score 9 (7–12)
CS on admission 3 (3–3)
irst cardiac rhythm
Asystole/pulseless activity 33
Ventricular arrhythmia 34
ime from collapse to basic life support (min) 6 (3–10)
uration of CPR (min) 15 (5.5–25)
hite blood cells (109/l) 14.5 (11.3–18.7)
ematocrit (%) 42 (39–46)
actate (mmol/l) 5.2 (2.6–10)
nterleukin-6 (pg/ml) 158 (53–400)
KA 10
rotein C (%) 70 (34–100)
VKA 79 (59–97)
VKA 13 (7–28)
rotein S (%) 60 (40–78)
VKA 66 (44–80)
VKA 25 (13–35)
T (s) 19.6 (15.2–28)
VKA 17 (15–26)
VKA 28 (24–36)
PTT (s) 44 (36–54)
TM (ng/ml) 40 (32–56)
T (%) 88 (74–99)
latelets (109/l) 215 (176–280)
-dimer (g/ml) 9 (2.6–20)
AT complex (g/ml) 36.2 (14.8–122)
AP complex (g/ml) 2,754 (1,654–4,57
AP/TAT ratio 76 (39–133)
AI-1 (AU/ml) 22.5 (7.3–43)
ata are expressed as median (interquartile range).
APTT  activated partial thromboplastin time; AT  antithrombin; CPR  card
OD score  Logistic Organ Dysfunction score; NA  not applicable; PAI-1  p
ime; SAPS II score  Simplified Acute Physiology score; sTM  soluble thrombomantagonist therapy (n  10, with only one survivor); VKA  patients not receiving or
iomarker are reported in the Appendix.rst blood sampling at ICU admission was 2 h 30 min
interquartile range, 1 h 48 min to 3 h 36 min). Overt
nfection developed in 23 (34%) patients, 10 survivors
59%), and 13 (26%) nonsurvivors (p 0.03) with a median
ime to occurrence of two days (one to three days). All
nfections but one consisted of pneumonia (22 of 23, 96%),
he main cause being aspiration during the episode of
ardiac arrest. Of the 17 survivors, all were conscious at ICU
ischarge, and only one had severe cerebral damage. Of the
0 patients who died, 8 died within one day, 17 within two
ays, 22 within three days, and 30 within four days. The
emaining 20 patients died on day 5 or later. Of the 50
eaths, 20 (40%) were due to early refractory shock (Table
). No patients received hypothermia treatment. Of the 10
atients on oral anticoagulant therapy before admission,
nly one survived (p  0.43). Prior to admission, 8 patients
ere on chronic antiplatelet treatment; 29 additional pa-
ients received antiplatelet therapy at admission. Subcuta-
eous low-dose heparin was given to 48 patients during the
CU stay.
ter Successful Resuscitation of Out-Of-Hospital Cardiac Arrest
Survivors
(n  17)
Nonsurvivors
(n  50) p Value
55 (51–60) 59 (49–69) 0.45
52 (46–57) 70 (62–83) 104
7 (6–7) 11 (8–12) 104
4 (3–5) 3 (3–3) 0.0002
2 31 104
15 19
3 (1–6) 8 (5–10) 0.01
5 (5–10) 20 (10–30) 104
13 (11.3–18) 15 (12.2–18.8) 0.3
43 (38–43) 42 (39–46) 0.56
2.9 (1.6–4.5) 7.6 (4.2–11) 0.0002
57 (37–115) 222 (81–572) 0.001
1 9 0.43
86 (70–117) 61 (33–93) 0.048
90 (75–118) 72 (58–96) 0.08
11 16 (7–28) NA
68 (60–89) 55 (36–73) 0.07
69 (60–98) 65 (43–77) 0.15
30 23 (13–35) NA
16 (14–26) 19.7 (15.6–29) 0.27
16 (14–25) 18 (15–26) 0.36
27 28 (24–36) NA
43 (34–49) 47 (36–56) 0.27
35 (30–47) 41 (34–58) 0.19
96 (83–103) 87 (72–96) 0.11
220 (165–274) 214 (185–280) 0.36
5 (2.5–10.2) 15 (3–20) 0.04
26 (13–31) 54 (28–138) 0.004
2,336 (1,404–3,277) 3,489 (1,671–6,434) 0.15
89 (66–165) 64 (37–118) 0.01
22 (14–36) 23 (4.7–46) 0.84
onary resuscitation; GCS  Glasgow Coma Scale score; ICU  intensive care unit;
ogen activator inhibitor; PAP  plasmin antiplasmin complex; PT  prothrombin
; TAT  thrombin-antithrombin complex; VKA  patients receiving oral vitaminAf
6)
iopulm
lasmin
odulinal vitamin K antagonist therapy (n  57). Normal ranges and abbreviations of each
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Protein C Pathway Alteration After Cardiac Arrest July 5, 2005:21–8The positive control group was composed of 12 patients
9 men, 75%) with septic shock, a SAPS II score of 61 (48
o 74), a LOD score of 8 (6.5 to 9), a Glasgow Coma Scale
core of 13 (12 to 15), and a need for vasopressor therapy.
he lungs (n  7, 58%) and abdomen (n  3, 25%) were
he main sites of infection. Of these 12 patients, 7 (58%)
ied. The negative control group comprised 10 healthy
olunteers (Table 3).
nflammatory response. As described previously (5), IL-6
nd lactate levels were high in the OHCA group at
dmission, and high levels were associated with death
receiver-operating characteristic test: 0.76 and 0.81, respec-
ively). Both IL-6 and lactate levels were correlated to CPR
uration (r  0.46, p  0.0002; and r  0.45, p  0.0005,
espectively), but not to the time from collapse to basic life
upport. The large volume of fluid administered explains the
ecrease in hematocrit from 42% (39% to 46%) on admis-
ion to 36% (35% to 40%) on day 2 (p  104), and 39
atients (58%) required vasopressor therapy within the first
able 2. Baseline Characteristics of Patients Who Were Successf
rom Early Refractory Shock or Delayed Neurological Dysfunctio
Parameters
All Nonsurvivors
(n  50)
ge (yrs) 59 (49–69)
APS II score 70 (62–83)
OD score 9 (7–12)
CS on admission 3 (3–3)
irst cardiac rhythm
Asystole/pulseless activity 31
Ventricular arrhythmia 19
nterval from collapse to basic life support (min) 8 (5–10)
uration of CPR (min) 20 (10–30)
hite blood cells (109/l) 15.1 (12.2–18.8)
ematocrit (%) 42 (39–46)
actate (mmol/l) 7.6 (4.2–11)
nterleukin-6 (pg/ml) 222 (81–572)
KA 9
rotein C (%) 61 (33–93)
VKA 72 (58–96)
VKA 16 (7–28)
rotein S (%) 55 (36–73)
VKA 65 (43–77)
VKA 23 (13–35)
T (s) 19.7 (15.6–29)
VKA 17 (15–27)
VKA 28 (24–36)
PTT (s) 47 (36–56)
TM (ng/ml) 41 (34–58)
T (%) 87 (72–96)
latelets (109/l) 214 (185–280)
-dimer (g/ml) 15 (3–20)
AT complex (g/ml) 54 (28–138)
AP complex (g/ml) 3,489 (1,671–6,434)
AP/TAT ratio 64 (37–118)
AI-1 (AU/ml) 23 (4.7–46)
ata are expressed as median (interquartile ranges).
VKA  patients receiving oral vitamin K antagonist therapy (n  9); VKA 
n Table 1. Normal ranges and abbreviations of each biomarker are reported in thewo days. However, neither the need for vasopressors nor uhe magnitude of the hematocrit reduction was associated
ith mortality.
oagulation biomarkers at admission. At study entry, all
HCA patients had an inflammatory response and
oagulation abnormalities including increased coagula-
ion activation, reduced anticoagulation, and activated
brinolysis (Table 1). Baseline D-dimer levels were high
n all OHCA patients. Coagulation activation (elevated
AT, 100% of patients; decreased protein C, protein S,
nd AT) was associated with activated fibrinolysis (ele-
ated PAP, 100% of OHCA patients). All OHCA
atients had evidence of systemic inflammation (elevated
L-6, 100% of patients). However, at admission, 37% of
HCA patients had reduced fibrinolysis due to PAI-1
levation, and 28% had high sTM levels indicating
ndothelial injury, in contrast to results in the patients
ith septic shock. Furthermore, activation of coagulation
nd fibrinolysis and reduced anticoagulation at admission
ere more pronounced in nonsurvivors (Table 1), partic-
esuscitated After Out-Of-Hospital Cardiac Arrest Then Died
Nonsurvivors From Early
Refractory Shock
(n  20)
Nonsurvivors From
Neurological Dysfunction
(n  30) p Value
58 (42–69) 65 (49–72) 0.29
77 (67–90) 62 (57–72) 0.0014
12 (9–14) 9 (7–11) 0.008
3 (3–3) 3 (3–3) 0.69
22 9
8 11 0.07
8 (3.5–10) 7.5 (5.5–10) 0.57
20 (15–40) 15 (10–20) 0.05
14.4 (12.2–17.6) 16.5 (13–20) 0.49
45 (39–48) 42 (39–48) 0.18
10 (6.4–13.6) 4.7 (2.7–7.6) 0.002
407 (214–1,548) 98 (42–203) 0.0003
5 4 0.52
58 (17–83) 77 (52–100) 0.04
59 (36–86) 91 (71–102) 0.007
16 (7–17) (n  5) 25 (8–40) (n  4) 0.43
45 (35–69) 67 (48–78) 0.17
53 (42–73) 71 (60–102) 0.10
18 (13–35) (n  5) 26 (16–41) (n  4) 0.80
23 (17–38) 18 (15–25) 0.06
20 (16–29) 17 (14–21) 0.06
33 (25–38) 25 (20–32) 0.22
50 (40–76) 39 (35–51) 0.04
45 (35–62) 39 (32–44) 0.29
85 (68–91) 91 (83–99) 0.03
205 (181–269) 229 (193–305) 0.24
20 (8–20) 7 (2–20) 0.03
114 (40–257) 31 (12–81) 0.002
4,295 (2.067–14,529) 2,360 (1,375–3,688) 0.01
64 (28–129) 63 (38–117) 0.63
20 (13–46) 23 (16–39) 0.37
nts not receiving oral vitamin K antagonist therapy (n  41); other abbreviations as
dix.ully R
n
patie
Appenlarly those dying from early refractory shock (Table 2).
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July 5, 2005:21–8 Protein C Pathway Alteration After Cardiac Arresthese features are similar to those observed in patients
ith septic shock (Table 3).
ourse of coagulation abnormalities over the first two
ays in the ICU. After natural log transformation of the
oagulation parameters, the p values of the Shapiro-Wilk W
est were all above 0.10 (ranging from 0.43 to 0.89),
ndicating a normal distribution. Biomarker levels in
HCA patients over the first two days are shown in Figure
and Table 3. In the nonsurvivors, coagulation abnormal-
ties were more severe and less likely to resolve within two
ays. Nonsurvivors also showed more severe acquired defi-
iencies in anticoagulant factors at admission and less recovery
ver the first two study days, as compared to survivors. At all
ime points within the two-day period, protein C was less
han the lower limit of normal in 34 (51%) patients overall
nd 25 (44%) patients who were not taking oral anticoag-
lation. Survivors had significantly lower levels of TAT over
he study period than did the nonsurvivors. They also had
ignificantly less fibrinolysis activation (lower PAP levels;
ig. 1) and less fibrinolysis inhibition (less PAI-1 elevation,
ata not shown) over time than did nonsurvivors. The ratio
etween fibrinolysis activation and coagulation activation
PAP/TAT) was higher in survivors than nonsurvivors,
uggesting inadequate fibrinolysis in patients who died (p
.01; Fig. 1). Additionally, nonsurvivors had higher levels of
TM (marker for endothelial injury) and IL-6 (marker for
nflammation) than did survivors throughout the study
eriod (data not shown). For comparison, values obtained
rom healthy volunteers and patients with severe sepsis are
ummarized in Table 3.
Of the 16 patients who had assays of plasma endogenous
ctivated protein C, 14 (87%) had detectable levels (1
g/ml) at admission. Levels were detectable in 3 of the 12
25%) patients alive on day 1 and in 1 of the 9 patients alive
able 3. Coagulation Parameters in Healthy Volunteers (Negativ
roup), and Patients Admitted After Successfully Resuscitated O
Parameters
Healthy
Volunteers
(n  10)
Patients With
Severe Sepsis
(n  12)
hite blood cell counts (109/l) 7.2 (6.6–7.8) 12 (7.3–30)
ematocrit (%) 42.3 (42–44) 32 (30–35)
latelets (109/l) 255 (223–304) 168 (92–213)
L-6 (pg/ml) 0 (0–0) 713 (259–884)
rotein C (%) 125 (100–140) 35 (27–44)
rotein S (%) 103 (92–115) 41 (34–56)
TM (ng/ml) 45 (40–53) 100 (70–123)
T (%) 107 (107–110) 51 (41–139)
-dimer (g/ml) 0.25 (0.22–0.32) 4 (3.5–7)
T (s) 12.9 (12.4–13.1) 21 (19–28)
PTT (s) 39 (36–41) 67 (55–71)
AT complex (g/ml) 1.8 (1.8–2.1) 9.7 (6–15)
AP complex (g/ml) 441 (289–554) 528 (450–740)
AP/TAT ratio 235 (169–282) 53 (36–122)
AI-1 (AU/ml) 7.5 (5.7–10) 37 (24–86)
Data are expressed as median (interquartile ranges). p values are for comparisons be
anges and abbreviations of each biomarker are reported in the Appendix.n day 2 (Fig. 2). Activated protein C levels were detectable fin 2 of 6 patients (33%) with septic shock and in none of the
0 healthy volunteers (data not shown). Activated protein C
evels were closely correlated with TAT levels (r  0.68, p
0.008) and with the LOD score (r  0.61, p  0.01).
ISCUSSION
vidence of systemic coagulopathy was consistently present
n patients successfully resuscitated after cardiac arrest:
oagulation was activated, anticoagulant factors diminished,
nd fibrinolysis increased. This was associated with a tran-
ient initial increase of endogenous production of activated
rotein C likely followed by a secondary endothelial injury
nd dysfunctional protein C anticoagulant pathway.
Cytokines such as tumor necrosis factor-alpha, IL-1, and
L-6 are released into the circulation, up-regulating the
xpression of tissue factor (21), a major initiator of intra-
ascular coagulation, on monocytes and endothelial cells.
he thrombin generated in this process not only converts
brinogen to fibrin clot, but also has potent proinflamma-
ory effects. We found IL-6 elevation, which can be related
o several mechanisms such as whole-body ischemia-
eperfusion syndrome, bacterial or endotoxin translocation
rom the gut, and pulmonary aspiration (6). This systemic
ost-resuscitation response constitutes a sepsis-like syn-
rome in which systemic inflammation (6) and coagulation
ctivation (thrombin generation) may reinforce each other,
esulting in fatal multiorgan failure (14,16).
Consistent with previous results described by Böttiger
t al. (9), we found marked activation of coagulation and
brinolysis in patients after CPR. However, D-dimers
ere only slightly increased in the study by Böttiger et al.
9), suggesting that activation of blood coagulation was
ot adequately balanced by activation of endogenous
ntrol Group), Patients With Septic Shock (Positive Control
f-Hospital Cardiac Arrest
Cardiac Arrest Patients
p Value*
t ICU Admission
(n  67)
Day 1
(n  59)
Day 2
(n  50)
4.5 (11.3–18.7) 15.1 (10.3–21) 13.1 (9.6–17.1) 104
42 (39–46) 42 (37–45) 36 (35–40) 104
215 (176–280) 192 (155–262) 151 (117–190) 104
158 (53–400) 216 (72–811) 106 (38–415) 0.51
70 (34–100) 73 (25–99) 76 (32–102) 0.16
60 (40–78) 53 (22–71) 62 (33–82) 0.32
40 (32–56) 53 (36–89) 59 (40–119) 104
88 (74–99) 88 (78–95) 82 (70–101) 0.003
9 (2.6–20) 3.7 (2–15) 2.2 (1.1–4) 104
9.6 (15.2–28) 18.6 (15.5–30.7) 20.3 (15.5–28.3) 0.66
3.8 (36–54) 54.6 (41–70) 59.8 (45–74) 0.01
6.2 (14.8–122) 11.9 (6.7–32.6) 7.6 (4.7–13.3) 104
754 (1,654–4,576) 899 (450–1,749) 607 (415–996) 104
76 (39–133) 71 (41–124) 102 (43–132) 0.32
2.5 (7.3–43) 40.1 (22–86) 25 (15–40) 0.04
healthy volunteers, septic patients, and cardiac arrest patients at admission. Normale Co
ut-O
A
1
1
4
3
2,
2brinolysis, whereas D-dimers were dramatically elevated
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ifferences in patient populations: most of the patients
tudied by Böttiger et al. (9) did not recover spontaneous
irculation, and none survived beyond 48 h, whereas we
ncluded only patients who returned to spontaneous
irculation, and we had about one-fourth of our patients
ischarged alive and conscious from the ICU. Thus,
ctivation of endogenous fibrinolysis may lag behind
igure 1. Changes in coagulation over the first two intensive care unit day
urvivors (S) (open boxes) and 50 nonsurvivors (NS) (black boxes). Patient
f the 67 patients studied at admission, 8 died within one day and 17 wit
ime-course of coagulation markers between S and NS. Medians are shown
AP  plasmin-antiplasmin complex; sTM  soluble thrombomodulin;brin formation. CWe found decreases in protein C and S levels, with the
owest levels in nonsurvivors. Hemodilution may contrib-
te to decreased protein C and S levels. However, these
evels were already low at admission and remained low
ver the two-day study period, whereas the hematocrit
ell sharply over time (Table 3). This suggests that early
emodilution (4) did not account for the very early
rotein C and S consumption during and/or just after
7 patients successfully resuscitated after out-of-hospital cardiac arrest, 17
iving oral anticoagulation were excluded from the protein C and S graphs.
o days. Repeated-measures analysis of variance was used to compare the
es, 25th to 75th percentiles as boxes, and 5th to 95th ranges as error bars.
 thrombin-antithrombin complex.s in 6
s rece
hin tw
as linPR. A similar early decrease in protein C levels has
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July 5, 2005:21–8 Protein C Pathway Alteration After Cardiac Arresteen reported several hours before the onset of clinical
igns of severe sepsis (22).
We found a number of differences between patients with
HCA and severe sepsis regarding the profile of coagula-
ion/fibrinolysis activation: protein C and S depletion was
ess marked in the OHCA patients than in the patients with
evere sepsis (Table 3). Severe sepsis often begins insidi-
usly, whereas the acute insult associated with cardiac arrest
ay lead to a rapid spike in these biomarkers followed by
ore moderate but sustained abnormalities. Another expla-
ation may be related to the higher early mortality rate in
HCA patients (especially those with early refractory
hock); patients with the most abnormal values died early
within the first 48 h) giving the “artifactual” impression of
he median levels being rapidly “normalized” in the surviv-
ng patients.
Plasma concentrations of endogenous activated protein C
n patients and normal volunteers were usually undetectable.
nly a very short-lived and early increase was observed in
HCA patients at admission. The generation of activated
rotein C in plasma in healthy humans is dependent on
irculating concentrations of both protein C and thrombin
23). However, in patients with severe sepsis, conversion of
ndogenous protein C to activated protein C may be
mpaired because of endothelial dysfunction with down-
egulation of thrombomodulin and endothelial protein C
eceptor (23). Cardiac arrest is an acute event occurring at a
ell-defined time, which allows detection of early changes
n systemic biomarkers. We speculate that early endothelial
timulation with thrombin generation is responsible for the
remendous increase in protein C conversion to activated
rotein C, and that this phase is rapidly followed by
igure 2. Activated protein C levels in plasma of 16 patients successfully
esuscitated after out-of-hospital cardiac arrest. We observed an early
ransient increase in activated protein C levels at admission. Of the 16
atients, 4 died within one day and 5 within two days. Protein C levels
ere undetectable (1 ng/ml) in 2 of 16 patients (13%) at admission, 9 of
2 patients on day 1 (75%), and 8 of 9 patients (89%) on day 2. This
xplains the overlapping dot symbols. None of the healthy volunteers
xhibited detectable levels of activated protein C.ndothelial dysfunction characterized by an inability to penerate an adequate amount of activated protein C. This is
onsistent with the increase in sTM levels over time (Table
), as sTM is a marker for endothelial injury. Moreover, in
n experimental baboon sepsis model, Taylor et al. (24)
bserved a similar profile, with a transient increase in
ndogenous activated protein C followed by a decrease. An
lternative hypothesis is that, among the five serine protease
nhibitors (namely, protein C inhibitor, alpha1-antitrypsin,
lpha2-antiplasmin, alpha2-macroglobulin, and PAI-1)
nown to inhibit activated protein C, the last four are
cute-phase reactants and increase during systemic inflam-
atory responses, which may diminish free levels of acti-
ated protein C (25,26). Support for this hypothesis comes
rom the significant increase in PAI-1 with a transient peak
n day 1 seen in our patients (Table 3).
At admission, activated protein C levels were closely
orrelated with thrombin generation, as reflected by TAT
omplex levels and organ dysfunction assessed by the LOD
core in the subset of patients whose activated protein C
evels were assayed. This suggests that increased generation
f thrombin and activated protein C reflect the progression
f organ dysfunction and disease severity. The rise in
ctivated protein C may reflect a natural compensatory
echanism that dampens the coagulation activation and
nflammatory response. Disseminated intravascular coagu-
ation is characterized by thrombin generation and fibrin
eposition, resulting in widespread microvascular thrombo-
is responsible for multiorgan failure, including neurological
ysfunction. Interestingly, activated protein C has been
hown to minimize ischemia/reperfusion injury to the dam-
ged spinal cord, and to the brain in stroke models (27–29).
his protective effect may be related to the anticoagulant,
nti-inflammatory, and antiapoptotic properties of activated
rotein C (29). This should encourage clinical studies to
etermine whether administration of thrombolytic or anti-
oagulant agents improves neurological outcome in OHCA
atients (13). Furthermore, early hemodynamic instability is
ndependent from subsequent neurological events (4), sug-
esting that aggressive initial treatment may be in order
ntil a reliable neurological assessment can be performed.
Our study has several limitations. It was completed before
he introduction of routine therapeutic hypothermia, which
ay interfere with coagulation (30). However, this treat-
ent is currently recommended only in a very small sub-
roup of patients (10%) (30). Patients with cardiac arrest
onstitute a heterogeneous population with a variety of
nderlying diseases (dominated by causes of cardiac isch-
mia) and often multiple treatments that may interact with
latelet aggregation or coagulation (as their intended effect
r as a side effect) before and/or during the ICU stay.
oreover, lifestyle, diet, and congenital deficiencies may
ffect coagulation pathways. Nevertheless, we found no
ignificant influence of drugs known to alter coagulation
ystems, and we believe that our patients are representative
f the overall population of successfully resuscitated OHCA
atients.
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Protein C Pathway Alteration After Cardiac Arrest July 5, 2005:21–8In conclusion, systemic coagulation abnormalities were
onsistently found in patients after recovery of spontaneous
irculation after cardiac arrest, and the profile of these
bnormalities was similar to that in patients with severe
epsis. The protein C depletion, transient increase in en-
ogenous activated protein C, gradual elevation in sTM,
nd systemic inflammatory response suggest that the protein
anticoagulant pathway may contribute to the high mor-
ality seen after CPR, as observed in patients with severe
epsis.
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ppendix. Abbreviations List and Normal Ranges
IL-6 and Coagulation
Parameters Normal Ranges
nterleukin-6 (IL-6) Less than the detection threshold
(0.7 pg/ml)
ctivated protein C Less than the detection threshold
(1 ng/ml)
rotein C (clot-based activity assay) 64%–161%
rotein S (clot-based activity assay) 55%–152%
oluble thrombomodulin (sTM) 18–53 ng/ml
ntithrombin (AT) (chromogenic-
based activity assay)
83%–130%
-dimer 0–0.6 g/ml
rothrombin time (PT) 12.5–14.9 s
ctivated partial thromboplastin
time (APTT)
26.9–35.1 s
hrombin-antithrombin complex
(TAT)
0–3.0 ng/ml
lasmin-antiplasmin complex
(PAP)
42–306 g/ml
lasminogen activator inhibitor-1
(PAI-1)
4.0–37.8 AU/ml
